Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.85
Bid: 21.90
Ask: 22.40
Change: 0.00 (0.00%)
Spread: 0.50 (2.283%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 21.85
ALL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Jun 2014 07:00

RNS Number : 6353J
Allocate Software PLC
16 June 2014
 



16 June 2014

 

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

 

Full Year Trading Update

 

Revenues in line, EBITDA and cash exceed market expectations

 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, today provides the following positive update on trading for its financial year ended 31 May 2014. The Company's audited results will be announced on 21 July 2014.

 

Overview

 

Allocate delivered another strong performance with full year revenues in line and EBITDA and cash ahead of market expectations.

 

Healthcare - UK Healthcare bookings exceeded revenue, driven by Allocate Cloud demand

 

The Healthcare business, the Group's main division and primary growth driver, produced another successful year and has continued to perform strongly. During the period, this division secured a significant number of contracts with both new customers and also for new products. Healthcare revenue has risen to 86% of Group revenue from 79% in 2013.

 

UK Healthcare bookings again exceeded revenue, driven principally by the accelerating deployment of the Allocate Cloud, which the Company launched in June 2013.

 

Adoption of Allocate Cloud has exceeded management's expectation with the number of new customers secured in 2014 being significantly higher than that in the prior year. The adoption rate is high due to the reliability, ease of deployment, cost saving and security offered by the service. All Allocate Cloud customers secured in 2013 have either renewed their agreement or are in the process of doing so. This means that over one third of Allocate's NHS HealthRoster customers are now operating on the Allocate Cloud.

 

HealthRoster, Allocate's core application, has maintained its strong growth with the number of new HealthRoster customers secured by the Company consistent with each of the prior two years. The high win rates of previous years have been maintained, as has the previous years' rate of competitive displacements. Additionally, the number of HealthRoster renewals significantly exceeded the number secured in the prior year with renewals continuing at the previously announced 100% rate.

 

The migration to HealthRoster V10 which was launched two years ago continues in line with management's plans. The number of HealthRoster V10 customers that are now live on the platform represents approximately 33% of the HealthRoster installed base, the number contracted and in process is over 50%. HealthRoster V10 adoption is key to sales momentum and the Company now has the platform required to be able to cross-sell new product lines to its installed base of customers.

 

SafeCare All-the-Time, the Company's new suite of applications which have been developed to support the drive within the NHS to improve the transparency of staffing levels, has been well received by customers and prospects. In 2014, some 15% of Allocate's NHS customers contracted for the first product of the new suite to be offered. On 5 June 2014, the full suite was announced and has already generated significant interest from the customer base. SafeCare All-the-Time will be an important growth driver in the next few years.

 

Sales of Allocate's Medics applications have progressed with the total number of new agreements secured slightly short of expectations due to a change in product mix; however these applications did achieve a high renewal rate of annual subscriptions.

 

As stated in the Company's interim results on 20 January 2014, sales of the Patient Flow and Emergency Department product lines have been slower than expected with decision making cycles being longer than originally anticipated. The year has shown strong levels of customer interest, but results have not met expectations.

 

The Company's international Healthcare operations continue to grow and again delivered results that have met management's expectations with both the Nordic and Australian regions achieving year-on-year growth.

 

As the Company enters the new financial year, the UK and Swedish Healthcare pipelines are strong, driven by high levels of customer engagement showing significant interest in our solutions.

 

 

Defence and Maritime- Long-term key customers continue to anchor strong position in sector

 

As stated in the Company's interim results on 20 January 2014, licence revenues from Allocate's defence and maritime divisions are harder to predict and no new customers were secured during the period. Notwithstanding, Allocate continues to maintain a strong position in the Defence and Maritime sector, with long-term key customers in the UK and Australia utilising its solutions and the Group's solution capabilities remain strong. In 2014 the two divisions combined accounted for 14% of Group turnover.

 

 

Ian Bowles, Chief Executive Officer of Allocate commented

 

"2014 was another strong year for Allocate, underpinned by compelling levels of organic revenue growth and a significant increase in profits and margins. We have responded quickly to the evolving requirements of the NHS and during the year have designed, built and deployed the capability to provide the safe staffing reporting required of all NHS Trusts by NHS England and NICE. Our core offering, HealthRoster, has maintained its market leading position. We have secured the same number of new HealthRoster customers as in each of the last two years and continued to renew 100% of HealthRoster term licenses. We more than doubled the number of Cloud customers as well as the number of customers that are now live on the V10 platform.

 

 

"Allocate closes the financial year 2014 with high levels of customer engagement and we remain confident that we are well positioned to continue to meet their needs and deliver on the strategy that we have laid out."

 

 

Allocate Software

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

 

 

 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Simon Willis / Richard Thomas

Corporate Broking - James Black

 

 

Tel: +44 (0) 20 7260 1000

FTI Consulting

Matt Dixon / Chris Lane

Tel: +44 (0) 20 3727 1000

 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA and Australia.

 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUOOVRSRANAAR
Date   Source Headline
28th Sep 20237:00 amRNS2023 Annual Financial Report
21st Sep 20237:00 amRNSNotice of Results and Investor Presentation
15th Sep 20237:00 amRNSConference Attendance
8th Sep 20237:05 amRNSInvestor Presentation
8th Sep 20237:00 amRNSUS$32.9m Strategic Investment
6th Sep 20237:00 amRNSResource and Exploration Drilling Results
4th Sep 20238:45 amRNSConference Attendance
30th Aug 20237:00 amRNSIssue of Equity - ESOP Options
22nd Aug 20237:00 amRNSIssue of Equity - Exercise of ESOP Options
17th Aug 20237:00 amRNSPartner Commits to Ewoyaa Development Funding
15th Aug 20237:00 amRNSMOU Signed for By-product Feldspar Study
10th Aug 20239:14 amRNSPCA Dealings
9th Aug 20239:30 amRNSDirector/PDMR Dealings
8th Aug 20237:00 amRNSResource and Exploration Drilling Results
7th Aug 20233:13 pmRNSStatement re Media Speculation
31st Jul 20237:00 amRNSQuarterly Activities and Cash Flow Report
19th Jul 20237:00 amRNSConference Attendance
13th Jul 20237:00 amRNSAppointment of Flotation Scoping Study Partner
30th Jun 20237:00 amRNSInvestor Presentation
29th Jun 20238:21 amRNSEwoyaa Definitive Feasibility Study
29th Jun 20237:17 amRNSEwoyaa Definitive Feasibility Study
23rd Jun 202311:00 amRNSBoard Appointments
20th Jun 20237:00 amRNSInitial Infill Drilling Results
16th Jun 20237:00 amRNSConference Attendance
13th Jun 20237:00 amRNSCorporate Update - Resignation of Director
1st Jun 20237:00 amRNSBoard Changes
26th May 20237:00 amRNSDTC Eligibility for OTCQX Electronic Trading
17th May 20237:00 amRNSConference Attendance
16th May 20237:00 amRNSAppointment of Chief Executive Officer
4th May 20237:00 amRNSConference Attendance
28th Apr 20237:00 amRNSQuarterly Activities and Cash Flow Report
26th Apr 20237:00 amRNSInternational Lithium Association Membership
19th Apr 20237:00 amRNSInfill Drilling and Passive Seismic Survey
6th Apr 20237:00 amRNSIssue of Equity – Exercise of ESOP Options
31st Mar 20237:00 amRNSIssue of Options
30th Mar 20237:00 amRNSConference Attendance
24th Mar 20237:00 amRNSCorporate Update - Director/PDMR Shareholding
22nd Mar 20237:00 amRNSDefinitive Feasibility Study Project Update
20th Mar 20237:00 amRNS2023 Exploration and Resource Programmes Update
20th Mar 20237:00 amRNSDirector/PDMR Shareholding
17th Mar 20237:05 amRNSInvestor Presentation
17th Mar 20237:00 amRNSHolding(s) in Company
15th Mar 20237:00 amRNSCorporate Update and Half-year Financial Report
9th Mar 20238:15 amRNSRestoration - Atlantic Lithium Limited
9th Mar 20238:00 amRNSResponse to Online Report & Restoration of Trading
8th Mar 20234:15 pmRNSSuspension - Atlantic Lithium Limited
1st Mar 20238:00 amRNSResults of Extraordinary General Meeting
21st Feb 20237:00 amRNSCommunications Update - Conference Attendance
17th Feb 20237:00 amRNSExpression of Interest - Investment by MIIF
13th Feb 20239:00 amRNSRicca Resources - Pre-IPO Placement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.